NY-ESO-1 PEPTIDE DERIVATIVES, AND USES THEREOF

Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

Description: NY-ESO-1 PEPTIDE DERIVATIVES, AND USES THEREOF RELATED APPLICATIONS This application is a continuation in part of Serial No 09/514,036 filed February 5. 2000, which is a continuation m part of Serial No 09/440,621 , filed November 15, 1999, which is a continuation in part of Serial No 09/165,546 filed October 2, 1998 which is a continuation in part of Serial No 09/062,422. filed April 17. 1998 which is a continuation-in-part of Senal No 08/937,263. filed September 15. 1997, which is a continuation-in-part of Serial No 08/725,182, filed October 3. 1996 now U S Patent No 5,804.381 All of these applications are incorporated by reference It is also a continuation in part of Senal No 09/275,993 filed March 25. 1999, which is a continuation in part of Serial No 09/049.850 filed March 27, 1998 FIELD OF THE INVENTION This ention relates to HLA binding peptides derived from an antigen associated with cancel These peptides bind to Class I molecules, and provoke lysis of the cells to which they bind by cytolytic T lymphocytes BACKGROUND AND PRIOR ART It is fairly w ell established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc are characterized by the inappropriate expression of certain molecules These molecules thus serve as "markers" for a particular pathological or abnormal condition Apart fiom their use as diagnostic "targets", l e . materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells Preparation of such materials, of course, presupposes a source of the reagents used to generate these Purification from cells is one labonous, far fiom suie method of doing so Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule. To date, two strategies have been employed for the detection of such antigens, in e.g., human tumors These will be referred to as the genetic approach and the biochemical approach. The genetic approach is exemplified by. e.g., dePlaen et aL Proc. Natl. Sci. USA 85 : 2275 ( 1988). incorporated by reference. In this approach, sev eral hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negatπ e variants of tumor cell lines which are tested for the expression of the specific antigen. The biochemical approach, exemplified by. e.g., O. Mandelboim, et aL, Nature 369' 69 ( 1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromography (HPLC). Antige c peptides are identified after they bind to empty MHC- class 1 molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytotoxic T-lymphocytes. These reactions include induction of CTL proliferation. TNF release, and lysis of target cells, measurable in an MTT assay, or a "'Cr release assay. These two approaches to the molecular definition of antigens have the following disadv antages first, they are enormously cumbersome, time-consuming and expensive; and second, they depend on the establishment of cytotoxic T cell lines (CTLs) with predefined specificity. The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods ha\ e. so far. succeeded in defining only very few new antigens in human tumors. See, e.g., van der Bruggen et al.. Science 254 1643- 1647 ( 1991 ); Bπchard et al., J. Exp. Med. 1 78 : 489-495 ( 1993); Cou e, et al., J. Exp Med. 180: 35-42 ( 1994); awakami, et al., Proc. Natl. Acad. Sci. USA 91 : 3515-3519 ( 1994) Further, the methodologies described rely on the av ailability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by. e.g.. Oettgen, et al.. Immunol. Allerg. C n. North. Am. 10: 607-637 ( 1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens. One key methodology is described by Sahin. et al., Proc Natl Acad. Sci. USA 92. 1 1810- 1 1913 ( 1995), incorporated by reference Also, see U S Patent No.5.698,396. and Patent Application Serial No. 08/479,328 filed January 3, 1996 All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA hbranes in a prokaryotic host (The libraries are secured from a tumor sample) The expressed hbranes are then nnmnoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses This methodology is known as the SEREX method ("Serological identification of antigens by Recombmant Expression Cloning") The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones See the above referenced patent applications and Sahin, et al . supra, as well as Crew , et al . EMBO 1 144 2333-2340 ( 1995) The SEREX methodology has been applied to esophageal cancer samples, and an antigen has now been identified, and its encoding nucleic acid molecule isolated and cloned See, e.g., U.S Patent No 5,804,381. referred to supra The antigen and truncated forms have been found to be reactiv e with antibodies in the serum of cancer patients It has also been found that peptides derived form this molecule bind with MHC molecules, provoking both cytolytic T cell and helper T cell responses It has been found that variations of these peptides can be used as well One difficulty in the area of cancer immunology is a lack of reliable protocols which can be used to identify and to quantify in ivo cytolytic T lymphocyte responses As a result, it is difficult to characterize immune lesponse, and to momtoi v accine trials It has been found that analysis of cytolytic T cells is greatly facilitated by the use of complexes containing a plurality of T cell targets More specifically, these complexes relv on the known a idity of two binding partners, such as avidin or streptavidm and biotm for each other It is well known that every molecule of avidm streptavidm can bind to four biotm molecules Constructs where the avidm/streptav idm-biotin system is used to form complexes containing multiple targets for cytolytic T cells, 1 e , a plurality of immune complexes which comprise an MHC molecule, such as an HLA molecule, a B2 microglobulm. and a peptide which binds to the HLA molecule are taught in, e.g Serial No 09/049,850, filed March 27, 1998. and incorporated by reference. The complex is labelled, and can be used to isolate, or to determine, cytolytic T cells of interest in a sample Such complexes hav e been utilized in the invention w Inch follow s BRIEF DESCRIPTION OF THE FIGURES Figure 1 presents data relating to the antigemcitv ot peptides and peptide analogues .elated to NY-ESO-1 Figures 2A and 2B show . respectiv ely, results relating to the in vitro lmmunogemcitv of NY-ESO-1 peptides and analogues (2A). and results of ELISPOT assays (2B) DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Example 1 Analvsis ot NY-ESO- 1 , as discussed in e g , U S Patent No 5.804 381. showed that a presenting molecule for this antigen was HLA-A2 Hence, a screening of the ammo acid sequence toi \Y-ESO-l was earned out. to identify all peptides w hich satisfy this HLA-A2 binding motif, using the model set forth bv DAmaro et al . Human Immunol 43 13-18 (1995), and Dπjfhout. et al , Human Immunol 43 1 -12 ( 1995 ) incorporated by reference Peptides corresponding to all of the ammo acid sequences deduced thereby were synthesized, using standard techniques, and were then used in cytotoxicity assays, following Knuth et al., Proc Natl Acad Sci USA 81 351 1 -3515 ( 1984), incorporated bv leference Specifically, cell line CEMX721 174 T2 ("T2" hereafter), was used, because it expresses HLA-A2, but does not process antigens to MHC complexed peptides. thereby making it ideal for expenments of the type described heiem Samples of T2 cells were labelled w ith 100 uCi of Na( Cr)0 4 , using standaid methods, and w ere then washed three times, follo ed by incubation with 10 ug ml peptide and 2 5 ug ml of B2-microglobuhn Incubation w as loi one hour, at room temperature Then l espondei cells ( 100 ul of a suspension of CTL NW38-IVS- 1 ) were added, at an effector target l atio of 90 1. and incubated for four hours in a w ater saturated atmosphere, ith 5% CO at 37 °C Then, plates w ere centπfuged at 200xg for fiv e minutes. 100 ul of supernatant was lemov ed. and radioactivity w as measured The percentage of Cr release was determined in accordance vv ith known strategies it was found that the peptides SLLMWITQCFL (SEQ ID NO l ). SLLMWTTQC (SEQ ID NO 2), and QLSLLMWIT (SEQ ID NO 3). were the three best stimulatois of HLA-A2 restricted NY-ESO- 1 specific CTLs Comparable results were found when NW-MEL-38 and cell lines SK-MEL-37 and MZ-MEL-19 were used as targets Example 2 In the next set of experiments, the ability of SEQ ID NOS 1 , 2 and 3 to bind to HLA-A2 molecules and to provoke CTL lysis was confirmed Samples of lymph nodes or metastatic lesions were taken from a patient who presented slow ly progressive melanoma with recurrent metastases. all of vv Inch were localized to the same parav ertebral legion Reverse transcnptase of RNA taken from a subject's tumor indicated that it expressed NY-ESO-1 Further, the patient's serum indicated high titer of antι-NY-ESO-1 antibodies The surgically resected lymph nodes or metastatic lesions were finely minced in stenle, RPMI 1640 medium that had been supplemented with 10% fetal calf serum Suspensions of cells wei e placed in 24-w ell tissue cultuie plates, in 2 ml of Iscov e's Dulbecco medium, supplemented with 0 24 m\l Asn. 0 55 niM Arg, 1 5 mM Gin, 10% pooled human A+ serum. 100 U/ml IL-2, and 10 ng/ml of IL-7 The cells were cultured for 2-3 weeks, prior to being assayed via IFN-γ ELISPOT, in accordance with Czerkmsky, et al, J Immunol Meth 110.29 (1998). incorporated by leference In brief. 2 \ 10' cells/well of the short term culture referred to supra were combined w ith either 5 x 10 4 T2 cells/well, or the same number of T2 cells, plus 1 uM of one of SEQ ID NOS 1 -3 Each culture was run in duplicate A mean number of 19 spots were counted in the control cultures, 424 spots with SEQ ID NO 2. 358 spots ith SEQ ID NO 3, and 396 with SEQ ID NO 1. These elevated numbers correspond to a frequency of about 1 NY-ESO-1 specific T cell per 20 tumor infiltrating lymphocytes The reactiv e T cells were then cultured to monoclonality in accordance w ith Valmoπ. et al. J Immunol 161 6956 ( 1998). incorporated by reference Fιve of24 TIL denved clones deriv ed for the TILs were found to be reactive w ith NY-ESO-1 derived peptides, when these weie tested v ia CTL assav s as described supra Example 3 In these expenments. CTL ES05. referred to supra, was tested for its ability to lyse A2" cells which either expressed or did not express NY-ESO-1 Cell lines NA8-MEL (A2", NY- ESO-1 ). SK-MEL37 (A2 . NY-ESO-1 ), and Me 275 (A2 . NY-ESO-1 ) were tested, in Cr release assavs. as described supra The results indicated that NA8-Mel was lysed when NY-ESO- 1 peptide SEQ ID NO 2 w as added, but not w hen it was absent Presence or absence of SEQ ID NO 2 was irrelevant to the lvsis of SK-MEL 37 and Me 2 7 5. both of which were lvsed under all conditions These l esults indicate that CTL ESO 5 l ecogmzes SEQ ID NO 2 when exogenouslv added, and presented endogenously Example 4 Expeπments w ere then carried out to determine w hich of SEQ ID NOS 1 , 2 & 3 constituted the optimal T cell epitope for lecogmtion by CTLs To determine this, synthetic peptides conespondmg to SEQ ID NOS 1. 2 and 3 ere tested m a functional competition binding assav . and then for lecogmtion by specific CTLs The tunctional competition binding assay employed is that taught by Valmoπ, et al . J Immunol 161 6956-6962 ( 1998 ). incorporated by reference, but elaborated upon herein The peptide YMDGTMSQV (SEQ ID NO 4) is known to bind to HLA-A'0201 molecules, and to provoke lysis by an HLA-A * 0201 restricted CTL clone, known as LAU 132/2 See \ almoπ. et al. Cane Res 59 2167 ( 1999) T2 cells were labelled with ''Cr, in the presence of anti class 1 monoclonal antibody W6/32 arying concentrations of SEQ ID NO 1 , 2, or 3 (50 .il) were incubated with 50 u\ samples of the labelled cells ( 1000 cells/well), for 15 minutes at room temperature Then, a suboptimal dose ( 1 nM) of SEQ ID NO 4 (50 ul) were added, together w ith 50 u\ of the T cells (5000 cells/w ell) Cr release was measured after 4 hours incubation at 37 C The concentration of each peptide lequned to achiev e 50%o inhibition of target cell lvsis w as then determined as [nM] 50% In order to facilitate the comparison, relative competitiv e activ as calculated as [nM] 50° o of reference peptide FluMA 58- 66 (SEQ ID NO 5 GILGFVFTL), w hich is a known high affinity HLA-A ' 0201 binder, divided by the [nM] 50% value determined for the test peptides The results indicated that SEQ ID NO 3 was a 100 fold less efficient competitor than SEQ ID NO 4 Further, SEQ ID NO 2 was 250 fold less efficient Surprisingly, given their tespective peptide lengths SEQ ID NO 1 was 10 fold more competitive than SEQ ID NO 2 These results suggested that cvsteme. as the carboxy terminal ammo acid or SEQ ID NO 2. w as the cause of poor binding to HLA-A2 molecules To investigate this, three derivatives of SEQ ID NO 2 were prepai ed. replacing carboxy terminal cvsteme with different hydrophobic amino acids containing non-polar side chains, such as alanme. leucine. or vahne (SEQ ID NOS: 6-8. respectively). The functional competition assay described supra was earned out with each of these peptides. The results are presented in Table 1 , which follows All substitutions clearly and dramatically enhanced peptide binding, for all three substituted peptides, indicating that any hydrophobic residue at their position would have similar effects. TABLE 1 Relative competitor Peptide Sequence activ ity Influenza A matrix 58-66 GILGFVFTL 1 NY-ESO- 1 155-163 QLSLLMWIT 0.01 157- 167 SLLMWITQCFL 0.04 157-165 SLLMWITQC 0.004 157-C165A SLLMWITQA 0.4 157-C165L SLLMWITQL 0.5 157-C 165V SLLMWITQV 10 Example 5 As indicated, supra, the peptides described herein were tested for recognition by specific CTLs In these experiments, target T2 cells were labelled with "'Cr for 1 hour, at 37°C, and then washed tw o times Sample ( 1000 labelled cells m 50 ul) were then incubated with varying concentrations of peptide, for 15 minutes Effector cells (50 ul) were then added These effector cells are ESOl specific CTL clone ES05 The lymphocyte, target ratio was 30: 1 Chromium release was measured after 4 hours of incubation at 37 °C. by testing 100 ul supernatant samples. Specific percent lysis was calculated as: [(experimental - spontaneous release)] 100 x (total - spontaneous release) The results, which follow m Table 2, are presented as the peptide nanomolar concentration giving 50% maximal activity. Also presented in Table 2 is the "relative antigemc activity" value, which is calculated as [nM] 50% of the peptide SEQ ID NO: 2 divided by [nM] 50% of the test peptide. Recognition of the analogue peptides by CTL was comparable to, or better than, the parental peptide. These results demonstrate that, among natural NY-ESO-1 peptides. SEQ ID NO: 2 was the optimally recognized antigemc peptide. Further, of the substituted peptides, SEQ ID NO: 8 w as recognized as efficiently as SEQ ID NO: 2, and the others were recognized more efficiently. SEQ ID NO. 6 was 1000 fold more efficiently recognized than SEQ ID NO: 2. TABLE 2 Peptide Peptide Relative antigemc Sequence ( [nM] 50%) activity SLLMWLTQC 0.6 1 SLLMWITQA 0.0005 1.200 SLLMWITQL 0.01 60 SLLMWITQV 1 0.6 QLSLLMWIT 50 0 012 SLLMWITQCFL 50 0.012 Example 6 This experiment describes the basic technique for making tetrameπc complexes of antigen, used in the examples which follow . In order to make the desired tetramers, it was first necessary to prepare constructs which would encode modified HLA-A * 0201 molecules. To do this, total RNA was extracted from HLA-A * 0201 positive cells, and HLA-A * 0201 was then cloned, using specific primers for the molecule, and reverse transcription polymerase chain reaction (RT-PCR) Airman et al., Science 274: 94-96 (October 4. 1996) but with a new 3' primer, i.e. 5'-GCAGGATCCCGGCTCCCATCCTCA GGGTGAGGGGC-3' (SEQ ID NO: 9) incorporated by reference, w as followed. Simultaneously with the RT-PCR. the ammo terminal nucleotide sequence was altered to optimize protein expression in the vector used. See Garboczi et al.. Proc. Natl. Acad. Sci. USA 89: 3429 ( 1992) incorporated by reference. Once this was done, the extracellular coding portion of the molecule was amplified, again using specific primers The resulting construct was recloned into a vector which would produce a BirA biotinvlation l ecogmtion site in frame at the 3'-end of the HLA-A'0201 heavy chain The modified HL A-A " 0201 and B2 microglobulin were ov erexpressed m separate E coh cultures The l esultiπg inclusion bodies w ere purified and the HLA and B2 microglobulin recombinant proteins w εi e solubihzed into urea, and then refolded, in a refolding solution, at 4 °C to form complexes (The refolding solution contained 100 mM Tπs. at pH 8 0. L-argmine, 400 mM. EDT A, 2 mM. I educed glutatlnone. 5 mM. oxidized glutatlnone. 0 5 mM, PMSF, 0 1 mM, HLA heav y chain, and β2 microglobulin 1 μM. and 10 μM of the peptide of mteiest) The refolding solution w as concentrated to 7 5 ml. using standard techniques Then, lefoldmg buffer was exchanged w ith BirA reaction buffei (Tπs 100 mM, pH 7 5, NaCl 200 mM. Mg CL 5mM, PMSF 1 00 L Vl leupeptin 1 uM, and pepstatm 1 uM). the last three being added immediately before use The complexes were then biotmvlated with biotm holoenzyme synthase (the BirA enzyme) bv combining the lefold mix containing the HLA-A2 complex with 50 μM enzyme, 100 mM biotm in 200 mM Tns. and 100 mM adenosme tπphosphate The mixture was incubated ov ernight at loom temperature The biotmylated complexes were then purified, and combined with phycoervthrm-labelled sti eptavid . to produce tetrameπc structures These were isolated, and reconstituted in small v olumes, at a concentration ot 1 mg/ml Example 7 These experiments w eie designed to assess the frequency of NY-ESO- 1 specific T cells Fluoiescent tetiamers of biotm. HLA-A2. and peptides w ere prepared in accordance with Romeio. et al. J Exp Med 188 641 ( 1998). and Altaian, et al. Science 274 94 ( 1996), Example 6. sum a. as ell as patent applications 09-275, 993 filed March 25, 1999 and 09/049, 850. filed March 27. 1998. both of which are incorporated by reference As antigemc peptides. Flu Ma 58- 66 (SEQ ID NO 5). and the ESO- 1 derivative using alanme as carboxy terminus (SEQ ID NO 6) w ei e used This derivativ e w as selected because of its high affinity, since high affimtv binding to HLA-A2 facilitates generation of stable tetramers Follow mg tetramer assembly, CTL clones specific for the peptides were combined with the appropriate tetramers in 20 ul of PBS with 2% FCS. and incubated at room temperature for 1 hour, followed by addition of either 20 ul of antι-CD8 antibodies labeled with FITC. or a mixture of antι-CD8 antibodies labeled with FITC, and antι-CD45RA antibodies labeled with "CYC " This mixture was incubated for 30 minutes at 4°C. after which the cells were washed in the same buffer as described supra, and then analyzed by flow cytometry. The tetramers of the NY-ESO- 1 derivative (SEQ ID NO: 6) specifically stained ESO 5, but did not stain the T cells specific for FluMa. and vice versa. Example 8 These experiments were designed to validate the use of tetramers which contain NY-ESO- 1 peptides in detecting and isolating NY-ESO- 1 specific T cells. An enriched CD8 ' T cell sample which had been stimulated with either SEQ ID NO: 2, or the alainne terminal substitution ( SEQ ID NO: 6). (Stimulation was accomplished by loading autologaus antigens presenting cells with the peptide of interest). Tetramers were made, as described supra, and used to stam the CD8 cells fourteen days following stimulation. Cells were sorted, and tested by IFN-γ ELISPOT. as described supra. Only CDS tetramer cells were found to contain IFN-γ productive cells. Sorted CD8 ~ tetramer and CD8 tetramer cells were expanded for two weeks via PHA stimulation, and both populations were assayed, in a - 'Cr release assay, on Me 275 and T2 cells, described supra, which had or had not been pulsed with SEQ ID NO: 2. Only CDS ' tetramer cells were effective in killing both cells which had been pulsed with SEQ ID NO. 2 and cells pulsed w ith the alamne analog. Example 9 These experiments were designed to determine if NY-ESO- 1 antigen is processed mtracellularly to produce a peptide that is presented by HLA-A2 molecules, which in turn stimulates lysis by CTLs. Tetramers. as described m example 6. supra, were prepared, using the peptide of SEQ ID NO:2. These tetramers were then used to stain a sample of cells taken from a patient who had been diagnosed previously as having a NY-ESO-1 positive melanoma. See Dunbar. et al., J. Immunol 162( 12):6959-62( 1999) and Serial No.09/049.850. filed March 27. 1998, incorporated by reference. In bπef. however, peripheral blood lymphocyte ("PBL") samples were stained with tetramers for 15 minutes at 37° C, followed by washing m PBS/1% FCS at 37° C, followed by incubation with a labelled. antι-CD8 antibody for 30 minutes, on ice. The cells were then washed three times, in ice cold PBST % FCS. and were then analyzed via flow cytometry Positive cells were cloned, via pulsing the positive cells with 10 uM of the peptide of SEQ ID NO 2. and culturmg in 1L-2 (200u/ml) for 5 days Four of these positive CTLs were expanded, and tested in the experiments which follow Example 10 The CTLs descπbed supra were then tested for killing specificity To do so, samples of a cell line typed previously as being NY ESO- 1 positive, a cell line typed previously as being NY-ESO- 1 negative, samples of T2 cells w Inch had been pulsed with 1 uM of the peptide of SEQ ID NO 2, and samples of impulsed T2 cells were combined with the CTLs, in 1 1 and 0 3.1 effector/target ratios. Killing w as determined using the Cι l elease assay described supra. The results indicated that both the NY-ESO-1 positi e cells, and the T2 cells pulsed with SEQ ID NO.2 were killed, while the others vv ere not, demonstrating that intracellular processing of NY-ESO-1 results in the generation of a peptide winch is recognized by SEQ ID NO.2 specific CTLs Example 11 The experiments in this example were designed to determine whether a mixture of diffeient CTLs was responsible for the positive results obtained with SEQ ID NOS' 1, 2 and 3. or if a single CTL clone recognized all peptides In these experiments. T2 cells were pulsed with one of SEQ ID NO 2. SEQ ID NO 1. or a peptide consisting of NY-ESO- 1 ammo acids 157-166, i .e. SLLMWITQCF (SEQ ID NO. l l ) SEQ ID NO 3 was also tested, as was a peptide consisting of the first 8 ammo acids of SEQ ID NO 1 Varying concentrations of peptide were used to pulse T2 cells. As a control, SEQ ID NO 5 was used The same Cr release assay described supra was used Pπor to testing the CTLs. these were assayed to determine if they each expressed a single T cell receptor The results indicated that all T cells recognized SEQ ID NOS.2, 3 and 1 1. but failed to recognize SEQ ID NO: l or the truncated peptide 157-164. I e.. a peptide consisting of the first 8 ammo acids of SEQ ID NO. l 1 These indicate that all three peptides were recognized by clonal CTLs Example 12 The experiments set forth in this example were designed to determine the mtracellular processing requirements for generating the peptide of SEQ ID NO.2. Cerundolo, et al. Nature 345(6274) 449-52( 1990) have descπbed mutant processing cells which are characterized as having defined blocks in the MHC I processing pathways These cells were used in these experiments. Specifically, a parental cell line was used, i.e.. "line 45." as w ell as "line 1 74. " w hich was TAP. LMP2. and LMP7 negative, a transfectant of line 174, where the line as transfected with vectors encoding TAP1 and TAP2. and a transfectant of line .174 which had been transfected w ith vectors encoding TAP1. TAP2, and LMP7 (The abbreviation "TAP" refers to "transporter associated with antigen processing," and the abbreviation "LMP" refers to "low molecular mass polyprotem.") In addition to the transfectants described supra, all of the cells were transfected with vaccinia v lrus constructs which encoded NY-ESO- 1 , at a multiplicity of infection (M.O.I.) of 5, for 90 minutes As controls, equivalent numbers of cells ( 10 6 cells) w ere suspended in 50 μl of medium containing l OO M of lactacysetme, for 1 hour prior to addition of v accinia virus constructs. After the 90 minute infection period, cells were washed, and suspended in 5 ml of medium containing 1 uM of lactacystm, and grown overnight to allow expression of the vaccinia vector. LMP2 and LMP7 are proteosome subunits. The cells were then combined with CTLs m a "Cr release assay of the type descπbed supra The results indicated that the expression of vaccinia encoded NY-ESO-1 in TAP deficient cells failed to sensitize them for CTL lysis. On the other hand, the presence or absence of the proteosome subunits LMP2 and LMP7 did not impair the presentation of an epitope recognized by the CTLs The controls used support this, because .1 74/TAP cells did not present the peptide of SEQ ID NO 5. w Inch is known to be dependent on LMP7 for presentation, while transfection with a v ector encoding LMP7. or the addition of lactacysteme eliminated the block on presentation These results suggest, quite strongly, that a non-proteosomal protease is involved in the presentation of the NY-ESO- 1 epitope. Example 13 These experiments w ere designed to determine if peptide analogues of SEQ ID NO:2, prepared by modification of the C- terminal cvsteme residue, had changed immunogenicity. 51 Cr release assavs of the type supra were carried out, in which the peptide (SEQ ID NO:2), and target cells were combined with 200uM of either dithiothreital (DTT) or TCEP (Tπs 2 carboxymethyl phosplnne) The results indicate that, in the presence of reducing agent, antige city of SEQ ID NO:2 increased 10 fold Parallel experiments were earned out with SEQ ID NO:8, and there was no increase in antigemcity. Example 14 The results observed in example 13. supra, suggested testing modified peptides. In addition to the peptides of SEQ ID NOS: 7 and 8. a peptide of formula: SLLMWITQI (SEQ ID NO.12), was synthesized, as were the following l Omers: SLLMWITQCV (SEQ ID NO. 13) SLLMWITQCF (SEQ ID NO: 1 1 , descπbed supra) SLLMWITQCI (SEQ ID NO.14) SLLMWITQAL (SEQ ID NO: 15) SLLMWITQAI (SEQ ID NO.16) SLLMWITQAF (SEQ ID NO: 1 7) Further. SEQ ID NO:2 was prepared where the C-terminal cysteine was modified with an -NH 2 - CO-CH 2 sidecham. All of these peptides were tested in CTL assays of the type descnbed supra. The peptides of SEQ ID NOS:7. 8 and 12 all increase recognition by NY-ESO-1 157-165 specific CTLs by about 1000 fold, as compared to SEQ ID NO.2. The peptide of SEQ ID NO: 14 was also recognized more efficiently than SEQ ID NO:2. Example 15 In these experiments, the ability of different peptide analogues to stimulate proliferation of NY-ESO-1 specific CTLs was tested In brief. PBLs were taken from two melanoma patients who evidenced high titers of NY- ESO- 1 specific antibodies, using a standard assay These PBLs were then stimulated with either l OOnM oi l OnM. of either SEQ ID N0.2 or SEQ ID M 8 following standard protocols. Over a period of two weeks, SEQ ID N0'8 resulted m a 14 fold greater expansion of NY-ESO-1 specific CTLs Over a 3 week period, the expansion was 54 fold greater than that obtained using SEQ ID NO.2. These CTLs were stained with tetramers of the type described supra, using SEQ ID NO 2. and the staining was positive, indicating that the CTLs recognized the relevant NY- ESO- 1 epitope It is noteworthy that l OnM of SEQ ID NO.8 stimulated the CTLs. hile larger amounts of nativ e peptide were in fact necessary Further, in follow up experiments using standard methodologies, it was ascertained that the expanded CTLs described in this example were capable of killing NY-ESO-1 positive tumor cells. Example 16 These experiments were designed in order to assess reactivity of tetramers with NY-ESO- 1 derived peptides, as described supra Tetramers as described in examples 6 and 7 were prepared, using either the peptide of SEQ ID NO 2 or SEQ ID NO 6 These w ere then tested for their ability to stam a CTL clone know n to react with complexes of HLA-A2 and a NY-ESO-1 derived peptide. See. e.g., Valmoπ, et al. Cane Res (2000), incorporated by reference Staining was earned out as described, supra The results indicated that both tetramers stained CTL clones in a dose dependent manner. At the highest dose of peptides tested ( 100 μg/ml), fluorescence intensity was 10 1 above background The concentration of tetramer required for flourescent signalling of intermediate intensity was about 12 g/ml for tetramers using SEQ ID NO 2, and 3 μg/ml of SEQ ID NO:6. A further study examined stammg of a 14 day bulk culture of penpheral blood lymphocytes, following stimulation with SEQ ID NO.2, as descnbed supra Mean fluorescence intensity was equivalent for the two tetramers. over several different polvclonal populations. Hereafter, when reference is made to tetramers, they use SEQ ID NO 2 Example 1 1 This example describes the isolation of additional cvtolytic T lymphocytes specific to complexes of HLA-A2 molecule and SEQ ID NO.2 Peripheral blood mononuclear cells ("PBMCs") w ei e isolated from two melanoma patients w ho were HLA-A*0201 positive The CD8 * cells ere separated via magnetic cell sorting, using magnetic beads coated with CD8 specific antibodies CD8 cells were irradiated (30001 ads), and then used as antigen presenting cells ("APCs") The CD8 cells were stimulated by combining about 1 x10 cells/ ell with 2-4x10 (> APCs, and 1 μM of the peptide of SEQ ID NO 2 The cells and peptides weie cultured in 2 ml Iscov e ' s Dulbecco medium, supplemented with 0 24mM Asn, 0 55 mM Arg, 1 5 mM Gin, 8% pooled human A serum, human recombinant IL-2 ( 100 U/ml), and human, recombinant IL-7 ( 10 ng/ml) The cells w ere stimulated every week, and after two rounds of weekly stimulation, the two cultures tested revealed 9 8% and 2.5% CDS . HLA-A2/NY-ESO-1 tetramer positive lymphocytes The positive cultures were then tested to find CTLs which were positive to tetramenc complexes containing SEQ ID NO 2 and SEQ ID NO 6 Those that were positive to both were sorted and cloned via limiting dilution Two clones were selected as representative of the entire population These will be referred to hereafter as LAU 155/ 18 and LAU 50 13 These, together with cell line LAU 156/5. described by Valmoπ, et al. supra, are used in the experiments which follow Example 18 The three HLA-A2/NY-ESO-1 specific CTL clones described m the preceding example were tested for their ability to lyse target cells, using the Cr release assay described in examples 1 and 3. supra All three lines were able to lyse the TAP deficient T2 cells described supra efficiently after they had been pulsed with saturating concentrations of SEQ ID NO.2 Half maximal lvsis was observed at a 3 1 ratio of lymphocyte/target cells The three clones vvei e also able to lyse melanoma cell line Me 275 efficiently This cell line was derived from a lymph node metastasis taken from the same patient from whom one of the three CTL lines was derived, i.e., it is autologous to one of these. This melanoma cell line expresses good levels of NY-ESO-1 protein, mRNA, and also expresses the homologous gene LAGE-1 , taught by Lethe, et al, U.S. Patent No. 5,811,519 incorporated by reference. None of these CTLs recognized the allogenic cell line Me 242, also described supra. This line also expresses NY-ESO-1 and LAGE, but is HLA-A2 negative. When taken together, these data indicate that the three CTL clones are NY-ESO- 1/HLA- A2 specific and are tumor reactive. Example 19 These experiments describe a functional competition assay used to assess peptide binding to HLA-A2 molecules. The assay is described by Valmori. et al, J. Immunol 160: 1750-1758 (1988), incorporated by reference. The assay is based upon the inhibition of recognition of SEQ ID NO:4, as described in example 4, supra. The following peptides were tested, and the results of the competition assay are provided: Relative competitor Amino Acid Competitor activity activity to SEQ ID SEQ ID NO: Sequence [mM] 50% NO:2 2 SLLMWITQC 0.27 1 QLSLLMWIT 0.03 9 1 SLLMWITQCFL 0.02 13 6 SLLMWITQA 0.0003 900 7 SLLMWITQL 0.002 130 19 SLLMWITQS 0.02 13 8 SLLMWITQV 0.00006 4500 20 ALLMWITQA 0.0013 208 21 SALMWITQA 0.01 27 22 SLAMWITQA 0.001 270 23 SLLAWITQA O.0001 >2700 24 SLLMAITQA 0.004 68 25 SLLMWATQA 0.01 27 26 SLLMWIAQA 0.0002 1350 27 SLLMWITAA 0.00018 1500 These results show that, while about 0.3μM of SEQ ID NO:2 was necessary for 50% competition activity, 9- and 13-fold lower amounts were needed with SEQ ID NOS: 3 and 1, respectively. It will be seen that the peptides of SEQ ID NOS: 6 and 7 resulted in a marked increase in peptide binding, as did SEQ ID NOS: 8 and 19. The single Ala substituted peptides of SEQ ID NOS: 20-27 were synthesized as a first step in determining the role of single amino acids in binding to MHC molecules, and T cell receptor interaction. It had been shown, supra, that C-terminal cysteine was deleterious to binding, so the Ala substituted mutein, SEQ ID NO:6, was used as the base peptide. The results are presented supra. Substitution at position 2. as expected, led to a 100 fold reduction in peptide binding. Substitutions at positions 5 and 6 also resulted in a significant reduction of binding. Surprisingly, the peptide of SEQ ID NO:23 had much greater binding ability. Example 20 These experiments were designed to assess the efficiency of antigen recognition by NY- ESO-1 specific CTLs. To do this, peptide titrations were carried out, using a 4 hour 51 Cr release assay of the type described supra, suing the T2 cell line, also described supra. The standard of measurement was 50% maximal lysis of that achieved by SEQ ID NO:2. The amount of SEQ ID NO:2 needed for 50% lysis varied for the three CTL clones tested, i.e., clones LAU 50/13, LAU 155/18, and 156/5, described supra (7nM, 12nM, and 3nM). The results are presented in figure 1 , which shows that SEQ ID NOS: 1 and 3 were less efficient as antigens for all three of the clones. One clone (LAU 156/5) did not even detect SEQ ID NO:3. The analogues utilizing variants at the C-terminus were better antigens than SEQ ID NO:2 in general. SEQ ID NO:6 appeared to be the most efficient antigenic peptide. The concentrations required to obtain 50% of maximal lysis were 3-4 orders of magnitude less than SEQ ID NO:2, for all of the three clones. SEQ ID NOS: 7 and 19 were also recognized more efficiently, with variable increases. In one case, SEQ ID NO:7 showed a 10 5 fold increase in relative antigenic activity, but had minimal effect on a second CTL. SEQ ID NO 8 was recognized more efficiently by two of the three clones. With respect to the single alamne substitutions of SEQ ID NOS 20-27, each clone exhibited fine specificity of recognition SEQ ID NO.27 showed this most distinctly Two of the clones recognized it as well as they recognized SEQ ID NO 2, or better and one did not recognize it at all Two of the clones showed similar patterns of recognition All peptides at positions 3 to 7 appeared to be critical for recognition by all of the CTL clones Example 21 These experiments were carried out to evaluate the ability of various peptides to elicit specific l esponses Highly enriched CD8 cells secured from the PBMCs of melanoma patients were stimulated, in v itro, with one of SEQ ID NOS 1. 2. 3. 6. 7. 8 or 19, as descnbed m pnor examples One w eek aftei stimulation, they were stained w ith SEQ ID NO.2 containing tetramers. and antι-CD8 antibodies, as described supra Aftei a week, about 0 1 to 0.2%o of the CD8 " lymphocytes in the culture were tetramer positive SEQ ID NO.3 was a weak stimulator, while SEQ ID NO 1 and all of the carboxy substituted derivatives led to expansion of the populations, as compared to SEQ ID NO:2. These results ai e shown in figure 2A In a follow up experiment, cultures were tested in an IFN-γ ELISPOT assay, using manufactui er's instructions In bπef, plates were coated, overnight with, IFN-γ specific antibodies and washed six times T2 cells were added (5x 10 4 cells/well) together with responder T cells w ell), and lμM peptide Duplicate cultures w ere prepared, and incubated for 20 hours at 37 C Cells were then removed, and plates vver dev eloped with a second, biotmylated IFN-γ antibody and streptav ldin-alkalme phosphatase complexes Spots were counted, using a steieonncroscope The assay was earned out because testing peptide analogue dπven T cell expansion w ith tetramers may not detect specific T cells w Inch do not cross react with the parent sequence Figure 2B shows these results Comparable numbers of specific cells were obtained, whether SEQ ID NO.2. or a peptide analogue was used The results confirm that SEQ ID NO:3 has poor immimogenicity. and that the majority of specific T cells elicited with the carboxy substituted peptides do cross react fully with SEQ ID NO 2 The invention, as will be seen from the preceding disclosuie, relates to peptides, of sequence SLL WITQX (SEQ ID NO 10) heiein X is any ammo acid except cvsteme. is preferablv a hydrophobic ammo acid with a non- polai side chain, such as Ala. V al. Leu. He. Pro. Phe, Met, Tip or Gly or an amino acid with an uncharged polar side chain, such Ser. Asp. Glu, Thr or Tyr and is most preferably Ala. He, Val. Leu oi Ser These peptides may be used theiapeutically. v la admimstiation to a patient who is HL -A2 positiv e, and expresses NY-ESO- 1 in connection w ith a pathology, as well as diagnosticallv . i e . to determine if HLA-A2 positive cells ate present, or if relevant CTLs are present, and so forth In an alternate embodiment. X is tw o ammo acids, the first of which is cvsteme or alanine. and the second of w hich is anv ammo acid Preferabl . the second ammo acid is Phe, He. Val or Leu Most preferably in this embodiment, the first ammo acid is cysteme. and the second ammo acid is Phe or He. as in SEQ ID NO 1 1. oi 14 Yet another embodiment of the invention are analogues of the peptide set forth at SEQ ID NO 6. i e . peptides where at least one of the ammo acids in SEQ ID NO 6 other than the C terminal ammo acid has been substituted by Alanine SEQ ID NO 27 is especially preferred, but the other peptides set forth at SEQ ID NOS 20-26 are also a part of the invention The HLA-A2 molecule is an MHC Class I molecule, and T cells which respond to complexes of peptides and class I molecules are generallv CDS cells Exemplary of the peptides defined by the core sequence of SEQ ID NO ID NO 10 is the peptide defined by SEQ ID NO ID NO 6 This peptide. as indicated, binds to HLA-A2 molecules Hence it is a "markei " for HLA-A2. as w ell as a component of peptide/MHC complexes w hich stimulate pro feiation of CTLs, as is described supra Similarly, peptides hei e He. Leu oi Val is the carboxv terminus in the structure of SEQ ID NO 10 can be used The peptides may be combined w ith adjuvants to fonn therapeutic compositions Also a part of the invention are nucleic acid molecules which consist of nucleotide sequences (so- called "mmi-genes " ) which encode the peptides of the invention These mmi-genes can be incorporated into expression vectors, in operable linkage w ith a promoter Additional constructs w Inch encode more than one peptide of the invention, including multiple copies of one or more peptides. aie part of the inv ention These constructs may be. e g in the form of recombinant v ectors, or so-called "naked DNA". 1 e small nucleic acid molecules encoding the desired peptide or peptides Similarly, recombinant cells which include the DNA or the vectors, such as eukarvotic oi prokaryotic cells, are part of the invention The ability of these peptides to bind to HLA molecules makes them useful as agents for deteπmnmg presence of HLA-A2 positiv e cells, such as HLA-A*0201 positive cells, by determining w hether or not the peptides bind to cells in a sample This "hgand/receptor" type of reaction is well known in the art. and arious methodologies aie av ailable for determining it A furthei aspect of the invention are so-called ' mini genes" w hich carry information necessary to direct synthesis of peptides v la cells into which the mini genes are transfected Mini genes can be designed which encode one or more antigenic peptides, and are then transferred to host cell genomes v la transfection w ith plasnnds or via cloning into v accima or adenoviruses See e g . Zaiac et al , Int f Cancel 7 1 496 ( 1997) incorporated bv reference These l ecombmant v ectois, such as recombinant v accinia vuus v ectois. can be constructed so as to produce fusion proteins Foi example, as w as shown, supra fusion proteins can be constructed w heie one portion of the fusion protein is the desired tumor rejection antigen precursor, or tumor re j ection antigen, and additional protein oi peptide segments can be included Exemplary, but bv no means the only types of additional protein or peptide segments which can be added to the fusion proteins, are reportei proteins or peptides, l e , proteins or peptides which give an obseiv able signal so as to indicate that expression has occurred, such as green fluoresence protein Additional reporter proteins include, but are by no means limited to, proteins such as βgalactosidase. luciferase. dhfi. and "eGFP " oi enhanced gieen fluorescent protein, as described bv Cheng, et al , Nature Biotechnology 14 606 ( 1996), incorporated by reference, and so forth The v aπous reporter proteins av ailable to the skilled artisan can be. and are used, in different w avs Foi example, "GFP" and "eGFP" can be used to v isualize infected cells, thereby facilitating tracking when flow cytometrv is used, and the isolation of the cells so infected Other leportei proteins are useful when methods such as western blotting, immunoprecipitation, and so forth are used These techniques are standard in the art and need not be reiterated here Protein oi peptide segments vv Inch facilitate the cleavage of the tumor rejection antigen precursor or tumoi rejection antigen fiom the fusion peptide may also be included The fusion protein can include more than one tumor l ejection antigen, as described, supra , and can also include proteins or peptides which facilitate the deliv ery of the tumor rejection antigen or antigens to a relevant MHC molecule Such proteins and peptides are well known to the art. and need not be elaborated herein Also a part of the invention aie recombinant cells vv Inch have been ti ansfected with the l ecombinant leporter vectors described heiem Such cells mav be. e g . any type of eukaryotic cell, ith human cells being especially preferred Such cells can then be used, e g , to produce tumor l ejection antigen precursois or tumor rejection antigens They can also be used, in an ex v iv o context, to generate cytolytic T cells specific for particulai complexes of MHC molecules and tumoi i election antigens This can be done simply bv contacting the transfected cells to a souice of T cells, such as a blood sample, so as to provoke the proliferation of any cells in the sample specific to the complexes of MHC molecules and TR s (l e , tumor rejection antigens) produced follo ing expression of the fusion protein, and piocessmg of the TRA Such cells, w hen l endeied non-prohferativ e. can also be used as v accine materials, as thev w ill present the lelev ant complexes on then surface, and prov oke the same tv pe of T cell response in vivo, as is show n heiem Similarly, the v ectors can be used as v accine materials per se, and can be admi steied to a patient in need of a T cell response against complexes of MHC molecules and peptide on cell surfaces Of course, T cells generated ex viv o can also be used to treat patients The peptides may be combined w ith peptides from othei tumor rejection antigens to form 'polytopes Exemplary peptides include those listed in U S Patent Application Senal Numbers 08/672.351 08/71 8,964, now U S Patent No , 08 487.135 now U S Patent No 08 530,569 and 08/880,963 all of which are incorporated by reference Additional peptides w hich can be used are those descnbed in the following references, all of w hich aie incorporated by reference U S Patent Nos 5 405.940, 5.487,974, 5.519.1 17, 5.530 096 5.554.506, 5,554 724, 5,558,995. 5,585.461 5 589.334, 5.648.226, and 5,683.886, PCT International Publication Nos 92/20356, 94/14459 96/1057 7 . 96/21673, 97/10837, 97/26535. and 97 / 31017 as w ell as pending U S Application Serial No 08713,354 Polytopes are groups of t o or more potential!) immunogenic or immune stimulating peptides. w Inch can bejomed together in v arious v avs. to determine if this type of molecule vv ill stimulate and/or provoke an immune response These peptides can be joined together directly, or v la the use of flanking sequences See Thompson et al . Proc Natl Acad Sci USA 92( 13) 5845-5849 ( 1995), teaching the direct linkage of l elev ant epitopic sequences The use of polytopes as vaccines is well known See, a Gilbert et al . Nat Biotechnol 15(12) 1280- 1284 ( 1997) Thomson et al . supra. Thomson et al I Immunol 157(2) 822-826 ( 1996), Tarn et al . I Exp Med 171( 1 ) 299-306 (1990), all of w Inch aie incorporated bv reference The Tam reference in particular shows that polytopes, w hen used in a mouse model, aie useful in generating both antibody and protective immunity Furthei the reteience shows that the polytopes. vv hen digested, yield peptides which can be and are piesented by MHCs Tam sho s this bv showing recognition of individual epitopes processed from polytope 'strings via CTLs This approach can be used, e g , in determining how manv epitopes can be joined m a polvtope and still provoke l ecogmtion and also to determine the efficacv of different combinations of epitopes Different combinations may be 'tailor-made' for the patients expressing particular subsets of tumor rejection antigens These polytopes can be intioduced as polypeptide structures, or v ia the use of nucleic acid delivery systems To elaboi ate the art has manv different ays av ailable to introduce DNA encoding an individual epitope oi a polytope such as is discussed supra See. e g . Allsopp et al , Eur J Immunol 26(8), 1951 - 1959 ( 1996), incorporated by reference Adenov irus, pox-virus, Ty-virus like particles plasnπds, bacteria, etc , can be used One can test these systems in mouse models to determine v Inch system seems most appropriate for a given, parallel situation in humans They can also be tested in human clinical trials Also, a feature of the invention is the use of these peptides to determine the presence of cvtolytic T cells in a sample It w as show n, supra, that CTLs in a sample will react with peptide MHC complexes Hence, if one knows that CTLs are in a sample, HLA-A2 positive cells can be Ivsed" by adding the peptides of the invention to HLA-A2 positive cells, such as HLA-A A201 positive cells, and then determining, e g . radioactive chromium release, TNF production, etc or any other of the methods by w hich T cell activity is determined Similarly, one can determine whether or not specific tumor infiltrating lymphocytes ("TILs") are present in a sample, by adding one of the claimed peptides with HLA-A2 positive cells to a sample, and determining lysis of the HLA-A2 positive cells v la, e g , Cr release, TNF presence and so forth In addition. CTL may be detected by ELISPOT analysis See for example Schmittel et al , ( 1997) I Immunol Methods 210 167-174 and Lalvani et al , ( 1997) J Exp Med 126 859 or by F ACS analysis of fluorogemc tetramer complexes of MHC Class I/peptide (Dunbar et al . ( 1998) Current Biology 8 413-416, Romero, et al . J Exp Med 188 1641-1650 (1998) All are mcoiporated by reference To elaborate, the complexes compπse a first binding partner and a second binding partner, wherein the first and second binding partner are specific for each other. These can be. e.g., avidin or streptavidm and biotm. an antibody or a binding portion of an antibody specific to biotm. and so forth. The key feature is that the second binding partner must be bound to a plurality of complexes of an MHC molecule, a β2 microglobulin molecule and a peptide w Inch binds specifically to said MHC molecule, and the multicomponent complex must be labelled. The MHC molecules are preferably HLA-A2 molecules; however, it will be understood by the artisan of ordinary skill that any HLA molecule could be used. Preferably, the second binding partner is biotm. but it may also be, e.g., an antibody w hich is specific for a component of the HLA/B2 microglobuhn/peptide complex, such as an HLA specific antibody, or a B2 microglobulin specific antibody Similarly, the first binding partner may be e g., recombinant or naturally occurπng protein L. recombinant or naturally occurring protein A. or even a second antibody The complex can be in soluble form, or bound, e g.. to a removable solid phase, such as a magnetic bead The number of HLA/B2 microglobulin/peptide complexes in the large molecule of the invention may vary It comprises at least two complexes, and preferably at least four, but more may be present as well. The complex of binding partners and HLA/B2 microglobuhn/peptide may be labelled, using any of the labels known to the art Examples of fluorescent labels are given supra. Enzymatic labels, such as alkaline phosphatase, metal particles, colored plastics made of synthetic materials, radioactiv e labels, etc . may all be used A third binding partner may also be used, which binds, specifically, to the first binding partner For example, if the first binding partner is streptavidm. and the second binding partner is biotm. then the third binding partner may be a streptavidm specific antibody When three or more binding partners are used, the label referred to supra may be attached to any of the binding partners so long as engagement with the HLA'B2 microglobulin peptide complexes is not impaired. The complexes may be used, e.g., to identify or to isolate cytolytic T cells present in a sample, w here these cells are specific for the HLA B2 microglobulin. peptide complex. Such cytolytic T cells bind to the lmmunocomplexes of the invention In a preferred embodiment, the sample being tested is treated w ith a reactant which specifically binds to a cytolytic T cell, wherein said label provides a detectable signal. The sample, including labelled CTLs, is then contacted to the complex, here it binds, and can be separated via any of the standard, well known approaches to cell separation Preferably, FACS is used, but other separation methodologies will be known to the skilled artisan as well The peptide used is left to the needs of the skilled artisan, and will depend, e.g., on the nature of the specific MHC system under consideration Additionally, the method can be used to monitor the status of tumors, following administration of a particular therapeutic agent, such as a v accine Further, since the methodology can be used to identify cytolytic T cell precursors, as show n, supra, one can identify candidates for potential therapies by determining if they possess the relevant T cell precursors Of course, the peptides may also be used to provoke production of CTLs. As was shown, supra, CTL precursors develop into CTLs when confronted w ith appropriate complexes By causing such a "confrontation " as it were, one mav generate CTLs This is useful in an m vivo context, as ell as ex vivo, for generating such CTLs. Also a part of the invention are so-called "cocktails" comprising a plurality of different peptides, at least one of which is a peptide of the invention, as w ell as "polytope" molecules, and nucleic acid molecules encoding them "Polytope" as used herein, refers to a recombinant molecule designed to contain a plurality of peptide sequences which are presented by MHC molecules, following intracellular processing. Such polytopes can consist of a repeating epitope, a number of different epitopes. and so forth Other features and applications of the invention will be clear to the skilled artisan, and need not be set forth herein The teπns and expression which hav e been employed ai e used as terms of descnption and not of limitation, and there is no intention m the use of such terms and expression of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention

Claims: AIM: An isolated nonapeptide of formula SLLMWITQX ( SEQ ID NO 10) wherein X is an ammo acid having an uncharged polar side chain, heiein said nonapeptide binds to an HLA molecule and provokes lysis by cytolytic T cells The isolated nonapeptide of claim 1 , wherein said amino acid is Ser, Asp, Glu, Thr or Tyr The isolated nonapeptide of claim 1. wherein said ammo acid is Ser An isolated complex useful in isolating a cytolytic T cell, comprising a first and second binding partner which are specific to each other, wherein said second binding partner is bound to a plurality of complexes of an HLA-A2 molecule, a B2 microglobulin molecule, and the nonapeptide of claim 1 The isolated complex of claim 4. wherein said complex is a tetramer The isolated complex of claim 5. wherein X in SEQ ID NO 10 is Ser (SEQ ID NO 19) Composition useful in provoking a cytolytic T cell response comprising the isolated nonapeptide of claim 1 , and an adjuvant An isolated nucleic acid molecule consisting of a nucleotide sequence which encodes the nonapeptide of claim 1 The isolated nucleic acid molecule of claim 8, wherein said nonapeptide consists of the ammo acid sequence set forth at SEQ ID NO 19 10. Expression vector comprising a plurality of nucleotide sequences which encode peptides which bind to MHC molecules, wherein at least one of said peptides is the peptide of claim 1 1 1. The expression vector of claim 10, wherein at least one of said peptides consists of the ammo acid sequence of SEQ ID NO: 19. 12. Recombinant cell transformed or transfected with the isolated nucleic acid molecule of claim 8. 13. Recombinant cell transformed or transfected with the expression vector of claim 10. 14. Method for determining if a cell presents an HLA-A2 molecule on its surface comprising contacting a sample containing said cell with the peptide of claim 1 , and determining binding therebetween, said binding being indicative of HLA-A2 on the surface of said cell. 15. The composition of claim 7, further comprising at least one additional peptide. 16. Isolated polytope molecule, at least a portion of which comprises the ammo acid sequence of claim 1 17 A method for determining if a cytolytic T cell specific to complexes of an HLA-A2 molecule and a peptide is present m a sample, comprising admixing said sample with an HLA-A2 molecule and the nonapeptide of claim 1 , and determining interaction between said cytolytic T cell, and complexes of HLA-A2 molecule and said peptide to determine specificity of said cytolytic T cell. 18. The isolated complex of claim 4, further comprising a label. The isolated complex of claim 18. wherein said first binding partner is avidin and said second binding partner is biotm The isolated complex of claim 19. compns g complexes of MHC molecule, β2 microglobulin and peptide A method for identifying or isolating cytolytic T cells in a sample, comprising admixing said sample with the complex of claim 4. and identifying or isolating cytolytic T cells which bind thereto A method for monitoring status of a tumor, comprising contacting a sample taken from a patient vv ith a tumor with the isolated complex of claim 4 to determine cytolytic T cells in said sample, and comparing a v alue obtained to a prev iously determined value to determine status of said tumor An isolated nonapeptide which is an analogue of SEQ ID NO 6, wherein one ammo acid in SEQ ID NO 6 other than the C terminal amino acid has been leplace by alanine The isolated nonapeptide of claim 23, selected from the group consisting of SEQ ID NO 20. 21. 22. 23, 24. 25. 26 and 27 The isolated nonapeptide of claim 24, consisting of SEQ ID NO 27 An isolated nucleic acid molecule which encodes the nonapeptide of claim 23 Expression vector comprising a plurality of nucleotide sequences, at least one of which is the nucleotide sequence of claim 26 Recombinant cell transformed or transfected vv ith the isolated nucleic acid molecule of claim 26 Recombinant cell transformed or transfected with the expression v ector of claim 27 Method for determining if a cell presents an HLA-A2 molecule on its surface compnsmg contacting a sample containing said cell with the peptide of claim 23, and determining binding therebetween, said binding being indicative of HLA-A2 on the surface of said cell Composition useful in providing a cytolytic T cell lesponse, comprising the isolated nonapeptide of claim 23, and an adjuvant The composition of claim 31 , comprising at least one additional peptide Isolated polytope molecule, at least a portion of w hich comprises the ammo acid sequence of claim 23 A method for determining if a cyolytic T cell specific to complexes of an HLA-A2 molecule and a peptide is present in a sample, comprising admixing said sample with an HLA-A2 molecule and the nonapeptide of claim 23. and determining interactions between said cytolytic T cell, and complexes of HLA-A2 molecule and said peptide to determine specificity of said cytolytic T cell An isolated complex useful m isolating a cytolytic T cell, comprising a fist and second binding partner which are specific to each other, v herein said second binding partner is bound to a plurality of complexes of an HLA-A2 molecule, a β2 microglobulin molecule, and the nonapeptide of claim 23 The isolated complex of claim 35, wherein said nonapeptide is SEQ ID NO 20, 21 , 22, 23. 24. 25, 26 or 27 The isolated complex of claim 35, wherein the first binding partner is avidm and the second binding partner is biotm A method for identifying or isolating cytolytic T cells in a sample, comprising admixing said sample with the isoloated complex of claim 35. and identifying or isolating cytolytic T cells which bind thereto.

Inventors: CEROTTINI JEAN-CHARLES, CERUNDOLO VINCENZO, ROMERO PEDRO, VALMORI DANILA, CEROTTINI, JEAN-CHARLES, CERUNDOLO, VINCENZO, ROMERO, PEDRO, VALMORI, DANILA
Applicants: CHANCELLORS MASTERS & SCHOLARS, LUDWIG INST CANCER RES, CHANCELLORS, MASTERS & SCHOLARS OF THE UNIVERSITY, LUDWIG INSTITUTE FOR CANCER RESEARCH
Application year: 2000
Main classification: C07K7
IPC codes: A61K39, C07K7, C07K14, C07K19, C12N1, C12N5, C12N15, C12Q1, G01N33